Ana Filipa Fonseca
Director, Global RLT, Strategy & Early Portfolio Novartis
Ana Filipa Fonseca is a proactive and strategic leader with more than 12 years of experience in the global pharmaceutical industry and consulting. She currently serves as Director of Global Radioligand Therapy Strategy & Early Portfolio in Oncology, where she oversees early pipeline strategy and guides research and development teams to shape mid- and long-term plans in nuclear medicine, ensuring commercially successful and clinically meaningful innovation.
Ana’s career spans the full value chain—from medicinal chemistry research to regulatory development, Market Access, HE&OR, RWE, and early commercial strategy—giving her a uniquely integrated perspective on how to advance therapies from concept to market. She has led cross-functional initiatives across multiple disease areas, with a strong focus on oncology, respiratory and cardiology, and maintains a dedicated interest in women’s health.
Seminars
- Assessing the RLT landscape, providing insights into current target successes and guiding future discovery to accelerate development and patient impact
- Opportunities and challenges for RLT R&D, incl. target identification and prioritization (Understanding the rarity of “ideal” targets like PSMA and somatostatin receptors and the implications for success)
- Defining the strategic fit of RLTs, highlighting how they complement existing oncology modalities and enable precision, combination, and patient-tailored therapies
- Future Landscape: a glimpse to the future development of target selection
New Company for 2026
